XML 27 R17.htm IDEA: XBRL DOCUMENT

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2013
Subsequent Event [Abstract]
Subsequent Event [Text Block]	12. Subsequent Event On May 7, 2013, the Company announced it is discontinuing the Phase 2b clinical trial with tamibarotene for patients with advanced non-small-cell lung cancer, following the recommendation of an independent Data Safety Monitoring Committee. The Company is evaluating the reduction in expected costs that result from the clinical trial cessation.